Group 1 - The core viewpoint of the article is the launch of the "Action Plan for Promoting High-Quality Development of Public Funds" by the China Securities Regulatory Commission, marking a new phase of reform and efficiency improvement in the public fund industry [1] - The public fund industry in China has seen significant growth, with assets under management increasing from 8 trillion yuan to 36 trillion yuan over the past decade, highlighting its importance in the capital market [2] - The industry is shifting focus from scale to investor returns, emphasizing the need for a systematic capability building that resonates with investors, industries, and market demands [2] Group 2 - The article discusses the establishment of a platform-based research and investment (R&I) system by companies like Harvest Fund, which has been in place since 2009, focusing on an "all-weather, multi-strategy" investment approach [2] - Harvest Fund has developed a comprehensive talent cultivation system, covering over 20 sub-industries, and has formed cross-industry research groups to enhance collaborative research efforts [3] - The company is leveraging digital tools and technologies, such as big data and machine learning, to create a standardized R&I data system that facilitates high-quality investment decision-making [3] Group 3 - Harvest Fund emphasizes deep fundamental research as a core aspect of its investment strategy, with significant holdings in manufacturing, information technology, and scientific research sectors, totaling over 220 billion yuan [4] - The company is focusing on strategic emerging industries such as semiconductors, artificial intelligence, and biomedicine, having conducted over 2,000 company research sessions in the past year [4] - The implementation of the "Action Plan" is expected to enhance the role of public funds in wealth management, capital market stability, and support for the real economy and national strategies [4] Group 4 - The future outlook for the public fund industry is positive, with expectations for the emergence of outstanding investment institutions and long-lasting firms [5]

本文首发于公众号"私募排排网"。 （点击↑↑ 上图查看详情 ） 编 者按 私募排排网数据显示，截至2025年7月底，管理规模在20亿以下的私募管理人有7000余家，占比超 85%，是私募行业数量庞大的中坚力量。私募排排网推出 「打卡100家小而美私募」 栏目，聚焦管 理规模适中、策略特色鲜明的优质私募基金管理人。通过深度解析其投资方法论、风控体系及能力圈 建设，为投资者提供差异化的视角与洞察。本期打卡 —— 上海高恩私募 。 私募排排网数据显示，截至2025年7月底，在10-20亿规模私募中，上海高恩私募旗下产品 "上海高 恩医药进取3号A类份额"收益***%，夏普比率***，位列1-7月主观多头产品榜top10、股票策略 夏普榜top10。（ 点此查看收益 ） Part.0 1 公司概况 打卡100家小而美私募 上海高恩私募基金管理有限公司位于上海浦东新区，管理人登记编号：P1072816，是一家专注 于深度价值投资的私募管理人。公司由一批来自实业、拥有超过15年深厚产业背景的优秀专业投 资人共同创立。 基于对港股市场与医药板块的独到见解，善于从产业视角出发，构建了专属的深度价投体系，致 力于为投资者创造长 ...